Floatz logo

Regorafenib

Liver Metastasis

Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the Liver Metastasis cohort.

Asset / SponsorPhaseRating
Talaporfin
Light Sciences LLC
Phase 2BB
FLUOROURACILUM
National Taiwan University Hospital
Phase 3BB
Calcium folinate pentahydrate
National Taiwan University Hospital
Phase 3BB
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3B

View all 30 →

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →